ערך בספרים למניה: Third Harmonic Bio Inc. (THRD)

The development of immune drugs for allergies remains independent of economic cycles, as evidenced by the book value per share trend, where the current parameter equals 6.07. Third Harmonic Bio (THRD) attracts leading scientists through the uniqueness of its technologies. The primary growth driver will be the upcoming trial results for its urticaria inhibitor, while current R&D expenses are already priced in by investors.
thirdharmonicbio.com - פילוחים אנליטיים ומדדי מפתח (THRD)

The book value per share, equal to 6.07, determines the equity portion per security, measuring the actual value of net assets minus all liabilities. By analyzing the book value per share chart, an investor can assess the financial stability of Third Harmonic Bio (THRD) amid a lack of profitability and risks associated with dependence on a single immunology drug.